Literature DB >> 18767130

Consensus statement on iron overload in myelodysplastic syndromes.

John M Bennett1.   

Abstract

In May 2005 at the 8th International Symposium on Myelodysplastic Syndromes (MDS), a consensus meeting was held on iron overload in MDS (Seymour, Hematol Oncol Clin 2005; Suppl 1:18-25). The recommendations of the 2005 consensus meeting were discussed in the context of currently available evidence at the 9th International Symposium on Myelodysplastic Syndromes in Florence Italy, May 2007. The recommendations of the consensus working group are presented here. The recommendations are a continued refinement of the outcome of the 2005 consensus meeting and the ground-breaking work of others in this area (Seymour, Hematol Oncol Clin 2005; Suppl 1:18-25; Gattermann, Int J Hematol 2008;88:24-29; Alessandrino et al., Haematologica 2002;87:1286-1306; NCCN practice guidelines: Myelodysplastic Syndromes, version 2.2008). Copyright 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18767130     DOI: 10.1002/ajh.21269

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  36 in total

Review 1.  Optimizing therapy for iron overload in the myelodysplastic syndromes: recent developments.

Authors:  Heather A Leitch
Journal:  Drugs       Date:  2011-01-22       Impact factor: 9.546

Review 2.  Iron chelation therapy in myelodysplastic syndromes: where do we stand?

Authors:  Mhairi Mitchell; Steven D Gore; Amer M Zeidan
Journal:  Expert Rev Hematol       Date:  2013-08       Impact factor: 2.929

3.  Deferasirox therapy is associated with reduced mortality risk in a medicare population with myelodysplastic syndromes.

Authors:  Amer M Zeidan; Franklin Hendrick; Erika Friedmann; Maria R Baer; Steven D Gore; Medha Sasane; Carole Paley; Amy J Davidoff
Journal:  J Comp Eff Res       Date:  2015-08       Impact factor: 1.744

4.  Geographical variations in current clinical practice on transfusions and iron chelation therapy across various transfusion-dependent anaemias.

Authors:  Vip Viprakasit; Norbert Gattermann; Jong Wook Lee; John B Porter; Ali T Taher; Dany Habr; Nicolas Martin; Gabor Domokos; Maria Domenica Cappellini
Journal:  Blood Transfus       Date:  2012-07-12       Impact factor: 3.443

5.  Safety and efficacy of deferasirox in the management of transfusion-dependent patients with myelodysplastic syndrome and aplastic anaemia: a perspective review.

Authors:  Rebecca L C Adams; Robert J Bird
Journal:  Ther Adv Hematol       Date:  2013-04

6.  Clinical characteristics and management of iron overload in 631 patients with chronic transfusion dependency: results from a multicentre, observational study.

Authors:  Joan Cid; Luis Palomera; Matías Díaz; Concha Zamora; Fernando Solano
Journal:  Blood Transfus       Date:  2013-03-14       Impact factor: 3.443

7.  Iron chelation therapy in myelodysplastic syndromes.

Authors:  Emanuela Messa; Daniela Cilloni; Giuseppe Saglio
Journal:  Adv Hematol       Date:  2010-06-20

8.  Iron overload in patients undergoing hematopoietic stem cell transplantation.

Authors:  Vinod Pullarkat
Journal:  Adv Hematol       Date:  2010-09-08

9.  Red blood cell transfusion independence following the initiation of iron chelation therapy in myelodysplastic syndrome.

Authors:  Maha A Badawi; Linda M Vickars; Jocelyn M Chase; Heather A Leitch
Journal:  Adv Hematol       Date:  2010-03-23

10.  Update on the use of deferasirox in the management of iron overload.

Authors:  Ali Taher; Maria Domenica Cappellini
Journal:  Ther Clin Risk Manag       Date:  2009-11-02       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.